Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 18


Basigin is a druggable target for host-oriented antimalarial interventions.

Zenonos ZA, Dummler SK, Müller-Sienerth N, Chen J, Preiser PR, Rayner JC, Wright GJ.

J Exp Med. 2015 Jul 27;212(8):1145-51. doi: 10.1084/jem.20150032. Epub 2015 Jul 20.


Stereochemical assignment of the protein-protein interaction inhibitor JBIR-22 by total synthesis.

Healy AR, Izumikawa M, Slawin AM, Shin-Ya K, Westwood NJ.

Angew Chem Int Ed Engl. 2015 Mar 23;54(13):4046-50. doi: 10.1002/anie.201411141. Epub 2015 Feb 4.


Interactions of peptide triazole thiols with Env gp120 induce irreversible breakdown and inactivation of HIV-1 virions.

Bastian AR, Contarino M, Bailey LD, Aneja R, Moreira DR, Freedman K, McFadden K, Duffy C, Emileh A, Leslie G, Jacobson JM, Hoxie JA, Chaiken I.

Retrovirology. 2013 Dec 13;10:153. doi: 10.1186/1742-4690-10-153.


A vaccine against CCR5 protects a subset of macaques upon intravaginal challenge with simian immunodeficiency virus SIVmac251.

Van Rompay KK, Hunter Z, Jayashankar K, Peabody J, Montefiori D, LaBranche CC, Keele BF, Jensen K, Abel K, Chackerian B.

J Virol. 2014 Feb;88(4):2011-24. doi: 10.1128/JVI.02447-13. Epub 2013 Dec 4.


Host Factors and HIV-1 Replication: Clinical Evidence and Potential Therapeutic Approaches.

Santa-Marta M, de Brito PM, Godinho-Santos A, Goncalves J.

Front Immunol. 2013 Oct 24;4:343. doi: 10.3389/fimmu.2013.00343. Review.


The isolation of novel phage display-derived human recombinant antibodies against CCR5, the major co-receptor of HIV.

Shimoni M, Herschhorn A, Britan-Rosich Y, Kotler M, Benhar I, Hizi A.

Viral Immunol. 2013 Aug;26(4):277-90. doi: 10.1089/vim.2012.0029.


Novel approaches and challenges to treatment of central nervous system viral infections.

Nath A, Tyler KL.

Ann Neurol. 2013 Sep;74(3):412-22. doi: 10.1002/ana.23988. Review.


Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1.

Pace CS, Song R, Ochsenbauer C, Andrews CD, Franco D, Yu J, Oren DA, Seaman MS, Ho DD.

Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):13540-5. doi: 10.1073/pnas.1304985110. Epub 2013 Jul 22.


Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases.

Flego M, Ascione A, Cianfriglia M, Vella S.

BMC Med. 2013 Jan 4;11:4. doi: 10.1186/1741-7015-11-4. Review.


Antiretroviral drugs: critical issues and recent advances.

Desai M, Iyer G, Dikshit RK.

Indian J Pharmacol. 2012 May;44(3):288-98. doi: 10.4103/0253-7613.96296.


CCR5 antagonism in HIV infection: current concepts and future opportunities.

Wilkin TJ, Gulick RM.

Annu Rev Med. 2012;63:81-93. doi: 10.1146/annurev-med-052010-145454. Epub 2011 Oct 27. Review.


Broad-spectrum inhibition of HIV-1 by a monoclonal antibody directed against a gp120-induced epitope of CD4.

Burastero SE, Frigerio B, Lopalco L, Sironi F, Breda D, Longhi R, Scarlatti G, Canevari S, Figini M, Lusso P.

PLoS One. 2011;6(7):e22081. doi: 10.1371/journal.pone.0022081. Epub 2011 Jul 19.


Pharmacological modulation of chemokine receptor function.

Scholten DJ, Canals M, Maussang D, Roumen L, Smit MJ, Wijtmans M, de Graaf C, Vischer HF, Leurs R.

Br J Pharmacol. 2012 Mar;165(6):1617-43. doi: 10.1111/j.1476-5381.2011.01551.x. Review.


Synergistic inhibition of R5 HIV-1 by maraviroc and CCR5 antibody HGS004 in primary cells: implications for treatment and prevention.

Latinovic O, Le N, Reitz M, Pal R, DeVico A, Foulke JS, Redfield RR, Heredia A.

AIDS. 2011 Jun 1;25(9):1232-5. doi: 10.1097/QAD.0b013e3283471edb.


Development of tetravalent, bispecific CCR5 antibodies with antiviral activity against CCR5 monoclonal antibody-resistant HIV-1 strains.

Schanzer J, Jekle A, Nezu J, Lochner A, Croasdale R, Dioszegi M, Zhang J, Hoffmann E, Dormeyer W, Stracke J, Schäfer W, Ji C, Heilek G, Cammack N, Brandt M, Umana P, Brinkmann U.

Antimicrob Agents Chemother. 2011 May;55(5):2369-78. doi: 10.1128/AAC.00215-10. Epub 2011 Feb 7.


Chemokine receptor 5 knockout strategies.

Cannon P, June C.

Curr Opin HIV AIDS. 2011 Jan;6(1):74-9. doi: 10.1097/COH.0b013e32834122d7. Review.


CCR5 antibodies HGS004 and HGS101 preferentially inhibit drug-bound CCR5 infection and restore drug sensitivity of Maraviroc-resistant HIV-1 in primary cells.

Latinovic O, Reitz M, Le NM, Foulke JS, Fätkenheuer G, Lehmann C, Redfield RR, Heredia A.

Virology. 2011 Mar 1;411(1):32-40. doi: 10.1016/j.virol.2010.12.029. Epub 2011 Jan 12.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk